Lin Frank, Vachiramon Vasanop, Casabona Gabriela, Cheung Jessie, da Cunha Ana Lúcia Gonzaga, Pavicic Tatjana, Spada Julieta, Fabi Sabrina
Monash University, Clayton, Victoria, Australia.
Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Cosmet Dermatol. 2025 Oct;24(10):e70449. doi: 10.1111/jocd.70449.
Microfocused ultrasound with visualization (MFU-V) is well established for noninvasive lifting of the face, neck, and décolleté. U.S. FDA clearance was recently granted for treatment of the abdomen and upper arms, supported by favorable safety data and emerging evidence of efficacy of its use to address skin and soft tissue laxity in body regions. Guidance on best practices for these additional indications is desirable.
This consensus aims to provide evidence-based and practice-informed recommendations supporting safe, effective, and reproducible MFU-V treatments for the additional body indications.
An international, multidisciplinary panel of aesthetic experts developed consensus recommendations for MFU-V treatment of additional body areas based on clinical evidence, expert experience, and structured virtual discussions.
This global expert consensus affirms MFU-V as a safe and effective noninvasive modality for treating mild to moderate skin and soft tissue laxity in the abdomen and upper arms. Three key domains were identified as critical to optimizing outcomes: patient selection, treatment planning, and expectation management. Ideal candidates are those with mild to moderate laxity and target tissues located at treatable depths. Real-time ultrasound imaging was emphasized for accurate targeting, anatomical safety, and treatment precision. The panel developed practical treatment protocols for the abdomen and upper arms, including recommended treatment zones, line densities, and transducer depths tailored to tissue characteristics.
Safe and effective MFU-V outcomes rely on real-time ultrasound visualization, thoughtful patient selection, expectation management, and anatomically guided treatment. Continued research is needed to refine protocols and guide emerging body applications.
可视化微聚焦超声(MFU-V)在面部、颈部和胸部的无创紧致方面已得到广泛应用。美国食品药品监督管理局(FDA)最近批准其用于腹部和上臂的治疗,这一批准得到了良好的安全性数据以及其用于改善身体部位皮肤和软组织松弛疗效的新证据的支持。对于这些新增适应症的最佳实践指南是很有必要的。
本共识旨在提供基于证据和实践经验的建议,以支持对新增身体适应症进行安全、有效且可重复的MFU-V治疗。
一个国际多学科美学专家小组基于临床证据、专家经验和结构化的虚拟讨论,制定了关于MFU-V治疗身体其他部位的共识建议。
这一全球专家共识确认MFU-V是一种安全有效的无创治疗方式,可用于治疗腹部和上臂的轻至中度皮肤和软组织松弛。确定了三个对优化治疗效果至关重要的关键领域:患者选择、治疗规划和预期管理。理想的候选患者是那些具有轻至中度松弛且目标组织位于可治疗深度的患者。强调使用实时超声成像以实现精确靶向、解剖学安全性和治疗精准度。该小组制定了针对腹部和上臂的实用治疗方案,包括根据组织特征推荐的治疗区域、线密度和换能器深度。
安全有效的MFU-V治疗效果依赖于实时超声可视化、谨慎的患者选择、预期管理以及解剖学引导下的治疗。需要持续进行研究以完善治疗方案并指导新出现的身体部位应用。